GlassScriptPhysician profile
Kenneth Finkelstein
NPI 1245222165
$10,324.49
in general payments reported to CMS, 2019-2025
54 companies · $942 in 2025
The $942 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
See the full distribution for Urogynecology and Reconstructive Pelvic Surgery (Urology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $1,126 · 2021: $2,419 · 2022: $1,173 · 2023: $2,574 · 2024: $763 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545 · Travel and Lodging: $812 · Consulting Fee: $505 · Debt Forgiveness: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,544.59 |
| Travel and Lodging | $811.77 |
| Consulting Fee | $505.00 |
| Debt Forgiveness | $418.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,302.70 | 2021-2024 | Interstim |
| Caldera Medical, INC | $1,148.24 | 2019-2021 | |
| Astellas Pharma US INC | $628.19 | 2019-2025 | Veozah, Myrbetriq, Padcev |
| Baxter Healthcare | $618.87 | 2022-2024 | Tisseel |
| Abbvie INC. | $572.79 | 2019-2025 | |
| Olympus America INC. | $430.85 | 2021-2025 | Olympus |
| Coopersurgical, INC. | $406.26 | 2019-2023 | Mara Console |
| Axonics, INC. | $327.57 | 2020-2023 | Axonics |
| Medtronic USA, INC. | $289.92 | 2019-2020 | |
| Gynesonics, INC. | $261.28 | 2022 | |
| Boston Scientific Corporation | $169.47 | 2019-2020 | |
| Exact Sciences Corporation | $134.46 | 2023-2025 | Cologuard Collection Kit |
| Momentis Surgical INC. | $134.00 | 2022 | |
| Aspira Women'S Health INC | $127.55 | 2021-2022 | |
| Allotrope Medical, INC | $119.92 | 2021 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.84 | 2021-2025 | Xifaxan |
| Organon LLC | $104.81 | 2022-2025 | Nexplanon, Jada System |
| Ethicon US, LLC | $98.38 | 2025 | Stratafix, Vistaseal |
| Novo Nordisk INC | $96.56 | 2020-2025 | Wegovy |
| Intuitive Surgical, INC. | $86.79 | 2019-2021 | |
| Shield Therapeutics INC | $84.64 | 2024 | |
| Allergan, INC. | $84.41 | 2019-2021 | |
| Hologic Sales and Service, LLC | $71.04 | 2020-2024 | Aptima |
| Glaxosmithkline, LLC. | $69.37 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Mylan Pharmaceuticals INC. | $69.33 | 2019-2022 | |
| Therapeuticsmd, INC. | $59.51 | 2019-2021 | |
| Laborie Medical Technologies Corp. | $57.28 | 2024-2025 | Urgent PC Neuromodulation System, Eclipse |
| Lilly USA, LLC | $56.86 | 2021-2025 | Zepbound |
| Lupin INC. | $55.08 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $53.76 | 2019-2024 | Exparel |
| Sumitomo Pharma America, INC. | $53.12 | 2023 | Myfembree |
| Merck Sharp & Dohme LLC | $41.32 | 2019-2021 | |
| Amgen INC. | $36.80 | 2023-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $34.15 | 2024 | Farxiga |
| Becton, Dickinson and Company | $33.98 | 2019-2020 | |
| Coloplast Corp | $29.92 | 2022 | |
| Scynexis, INC. | $28.00 | 2022 | |
| Agile Therapeutics, INC. | $24.74 | 2024 | Twirla |
| Biohaven Pharmaceuticals, INC. | $24.17 | 2021 | |
| Myovant Sciences INC. | $21.37 | 2021 | |
| Amag Pharmaceuticals, INC. | $20.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.81 | 2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.32 | 2022 | |
| Millicent US INC | $18.67 | 2025 | Femlyv |
| Channel Medsystems, INC. | $18.63 | 2023 | |
| Medline Industries LP | $17.58 | 2022 | |
| Pfizer INC. | $14.74 | 2023 | |
| Acessa Health INC. | $14.33 | 2019 | |
| Ambu INC. | $9.70 | 2024 | |
| Meditrina | $9.23 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,000,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Finkelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.